Biogen 경영진

경영진 기준 점검 2/4

Biogen CEO는 Chris Viehbacher, Nov2022 에 임명되었습니다 의 임기는 2.92 년입니다. 총 연간 보상은 $24.17M, 6.6% 급여 및 93.4% 보너스(회사 주식 및 옵션 포함)로 구성됩니다. 는 $1.97M 가치에 해당하는 회사 주식의 0.009% 직접 소유합니다. 경영진과 이사회의 평균 재임 기간은 4.7 년과 4.3 년입니다.

핵심 정보

Chris Viehbacher

최고경영자

US$24.2m

총 보수

CEO 급여 비율	6.62%
CEO 재임 기간	2.9yrs
CEO 지분 보유율	0.009%
경영진 평균 재임 기간	4.7yrs
이사회 평균 재임 기간	4.3yrs

최근 경영진 업데이트

Recent updates

CEO 보수 분석

Chris Viehbacher의 보수는 Biogen의 수익에 비해 어떻게 변했나요?
날짜	총 보수	급여	회사 수익
Jun 30 2025	n/a	n/a	US$2b
Mar 31 2025	n/a	n/a	US$1b
Dec 31 2024	US$24m	US$2m	US$2b
Sep 30 2024	n/a	n/a	US$2b
Jun 30 2024	n/a	n/a	US$1b
Mar 31 2024	n/a	n/a	US$1b
Dec 31 2023	US$4m	US$2m	US$1b
Sep 30 2023	n/a	n/a	US$1b
Jun 30 2023	n/a	n/a	US$3b
Mar 31 2023	n/a	n/a	US$3b
Dec 31 2022	US$30m	US$154k	US$3b

보상 대 시장: Chris의 총 보수(USD24.17M)는 CL 시장에서 비슷한 규모 기업의 평균(USD5.19M)보다 높습니다.

보상과 수익: Chris의 보상은 지난 1년 동안 20% 이상 증가했습니다.

CEO

Chris Viehbacher (64 yo)

2.9yrs

재임 기간

US$24,166,665

보수

Mr. Christopher A. Viehbacher, also known as Chris, is Director of Innocoll Holdings plc from July 24, 2017. He joined the Innocoll Holdings plc on July 24, 2017. He serves as President, Chief Executive Of...

리더십 팀

이름	직위	재임 기간	보수	지분
Christopher Viehbacher	President	2.9yrs	US$24.17m	0.0087% $ 2.0m
Nicole Murphy	Executive VP and Head of Pharmaceutical Operations & Technology	3.7yrs	US$5.74m	0.0097% $ 2.2m
Susan Alexander	Executive VP & Chief Legal Officer	19.8yrs	US$6.51m	0.038% $ 8.7m
Priya Singhal	Executive VP & Head of Development	5.8yrs	US$6.39m	0.0039% $ 889.9k
Robin Kramer	Executive VP & CFO	less than a year	데이터 없음	0.0055% $ 1.2m
Sean Godbout	Chief Accounting Officer & Global Corporate Controller	less than a year	데이터 없음	0.00033% $ 74.5k
Tim Power	Head of Investor Relations	less than a year	데이터 없음	데이터 없음
Adam Keeney	Executive VP & Head of Corporate Development	2.5yrs	데이터 없음	0.0016% $ 368.2k
Ginger Gregory	Executive VP & Chief Human Resources Officer	8.3yrs	US$5.08m	0.012% $ 2.7m
Alisha Alaimo	President & Head of North America	8.3yrs	데이터 없음	데이터 없음
Anabella Villalobos	Head of Biotherapeutics & Medicinal Sciences	8.3yrs	데이터 없음	데이터 없음
Natacha Gassenbach	Chief Communication Officer & Head of Corporate Affairs	5.8yrs	데이터 없음	데이터 없음

4.7yrs

평균 재임 기간

58yo

평균 나이

경험이 풍부한 관리: BIIB의 경영진은 경험이 있음으로 간주됩니다(평균 재임 4.7 년).

이사회 구성원

이름	직위	재임 기간	보수	지분
Christopher Viehbacher	President	2.9yrs	US$24.17m	0.0087% $ 2.0m
Stephen A. Sherwin	Independent Director	15.6yrs	US$440.16k	0.0077% $ 1.7m
William Hawkins	Independent Director	6.3yrs	US$470.16k	0.0060% $ 1.4m
Caroline Dorsa	Independent Chair of the Board	15.8yrs	US$629.84k	0.019% $ 4.3m
Eric Rowinsky	Independent Director	15.6yrs	US$455.16k	0.015% $ 3.4m
Maria Freire	Independent Director	4.3yrs	US$443.77k	0.0046% $ 1.1m
Lloyd Minor	Director	1yr	US$31.86k	0.0016% $ 365.9k
Monish Patolawala	Independent Director	1.8yrs	US$440.16k	0.0025% $ 571.4k
Menelas Nicolas Pangalos	Director	less than a year	데이터 없음	데이터 없음
Jesus Mantas	Independent Director	6.3yrs	US$469.55k	0.0067% $ 1.5m
Susan Langer	Independent Director	2.3yrs	US$425.77k	0.0035% $ 790.5k

4.3yrs

평균 재임 기간

66yo

평균 나이

경험이 풍부한 이사회: BIIB의 이사회는 경험이 있음으로 간주됩니다(평균 재임 4.3 년).

기업 분석 및 재무 데이터 상태

데이터	최종 업데이트 (UTC 시간)
기업 분석	2025/10/07 04:34
종가	2025/10/06 00:00
수익	2025/06/30
연간 수익	2024/12/31

데이터 소스

당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.

패키지	데이터	기간	미국 소스 예시 ^*
기업 재무제표	10년	손익계산서 현금흐름표 대차대조표	SEC 양식 10-K SEC 양식 10-Q
분석가 컨센서스 추정치	+3년	재무 예측 분석가 목표주가	분석가 리서치 보고서 Blue Matrix
시장 가격	30년	주가 배당, 분할 및 기타 조치	ICE 시장 데이터 SEC 양식 S-1
지분 구조	10년	주요 주주 내부자 거래	SEC 양식 4 SEC 양식 13D
경영진	10년	리더십 팀 이사회	SEC 양식 10-K SEC 양식 DEF 14A
주요 개발	10년	회사 공시	SEC 양식 8-K

^* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.

별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.

분석 모델 및 스노우플레이크

이 보고서를 생성하는 데 사용된 분석 모델의 세부 정보는 당사의 Github 페이지에서 확인할 수 있으며, 보고서 활용 방법에 대한 가이드와 Youtube 튜토리얼도 제공합니다.

Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.

산업 및 섹터 지표

산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.

분석가 소스

Biogen Inc.는 70명의 분석가가 다루고 있습니다. 이 중 34명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.

분석가	기관
David Toung	Argus Research Company
Brian Skorney	Baird
Ishan Majumdar	Baptista Research

Biogen 경영진

경영진 기준 점검 2/4

핵심 정보

최근 경영진 업데이트

High number of new directors

High number of new directors

High number of new directors

High number of new directors

Biogen Inc., Annual General Meeting, Jun 17, 2025

High number of new directors

Recent updates

Eisai Co., Ltd. and Biogen Inc. Announce U.S. Availability of Leqemab-irmb Subcutaneous Injection Main Maintenance Dose for Treatment of Early Alzheimer's Disease

Biogen Inc. to Report Q3, 2025 Results on Oct 30, 2025

Eisai Co., Ltd. and Biogen Inc. Announces Therapeutic Goods Administration Approves for the Treatment of Alzheimer's Disease in Australia

Biogen Inc. (NasdaqGS:BIIB) entered into a definitive agreement to acquire Alcyone Therapeutics, Inc. for $85 million.

High number of new directors

C4 Therapeutics Highlights Recent Achievement in Biogen Collaboration

Stoke Therapeutics, Inc. and Biogen Inc. Present Data At the 36Th International Epilepsy Congress That Support the Potential for Zorevunersen to Be the First Disease-Modifying Medicine for Dravet Syndrome

Biogen and Stoke Therapeutics Announce Presentations of Clinical Data from Studies of Zorevunersen for the Potential Treatment of Dravet Syndrome at the 36th International Epilepsy Congress

Stoke Therapeutics, Inc. and Biogen Inc. Announce First Patient Dosed in Phase 3 EMPEROR Study of Zorevunersen, A Potential Disease-Modifying Treatment for Dravet Syndrome

Second quarter 2025 earnings released: EPS: US$4.33 (vs US$4.01 in 2Q 2024)

Eisai and Biogen Present Results on Lecanemab Subcutaneous Autoinjector At AAIC 2025

Biogen Inc. Receives Positive Opinion from CHMP for the Treatment of Women with Postpartum Depression

Stoke Therapeutics, Inc. and Biogen Inc. Announce Presentation of Data from Studies of Zorevunersen, an Investigational Medicine for Dravet Syndrome, at the 16th European Paediatric Neurology Society (EPNS) Congress

High number of new directors

Biogen Inc. to Report Q2, 2025 Results on Jul 31, 2025

Biogen Inc. Initiates Phase 3 Study of Felzartamab for the Treatment of Primary Membranous Nephropathy

Biogen Inc. Announces New Data for Nusinersen Underscore Biogen's Commitment to Advancing Clinical Research to Improve Outcomes in SMA

Biogen to Advance Investigational Spinal Muscular Atrophy Asset to Registrational Studies Based on Positive Interim Phase 1 Results

Biogen Inc Initiates Phase 3 Pediatric Study of Omaveloxolone for the Treatment of Friedreich Ataxia

UCB and Biogen Inc. Announces Results from Phase 3 PHOENYCS GO Study Evaluating Dapirolizumab Pegol in Systemic Lupus Erythematosus

High number of new directors

High number of new directors

Biogen Inc., Annual General Meeting, Jun 17, 2025

Eisai Co., Ltd. and Biogen Inc. Announces Leqemab Marketing Authorization in the European Union

BioPharma Credit PLC Enters into Settlement Agreement with Biogen

Eisai Co., Ltd. and Biogen Inc. Reaffirms Positive Opinion for Lecanemab in Early Alzheimer's Disease

Biogen Inc. Provides Earnings Guidance for the Full Year 2025

High number of new directors

Eisai Co., Ltd. and Biogen Inc. Announce FDA Approves LEQEMBI (lecanemab-irmb) IV Maintenance Dosing for the Treatment of Early Alzheimer's Disease

Eisai Co., Ltd. and Biogen Inc. Announces FDA Accepts LEQEMBI (lecanemab-irmb) Biologics License Application for Subcutaneous Maintenance Dosing for the Treatment of Early Alzheimer's Disease

Biogen Inc. Announces Appointment of Adam Feire as Head of Business Development and External Innovation

Eisai Co., Ltd. and Biogen Inc. Announces Approval of ''LEQEMBI" (Lecanemab) for the Treatment of Early Alzheimer's Disease in Mexico

Eisai Co., Ltd. and Biogen Inc. Announce "LEQEMBI®" (Lecanemab) for the Treatment of Alzheimer's Disease Launched in South Korea

Samsung Bioepis and Biogen Receive European Commission (EC) Approval for Aflibercept Biosimilar, OPUVIZ

Eisai Co., Ltd. and Biogen Inc. Receive Positive Opinion from CHMP in European Union for Lecanemab in Early Alzheimer’s Disease

Eisai Co., Ltd. and Biogen Inc. Completes Rolling Submission to US FDA for LEQEMBI Biologics License Application for Subcutaneous Maintenance Dosing

Third quarter 2024 earnings released: EPS: US$2.67 (vs US$0.47 loss in 3Q 2023)

Biogen Inc. Appoints Daniel Quirk as Chief Medical Officer and Head of Medical Affairs

Biogen Inc. Announces Chief Financial Officer Changes

Biogen Inc. to Report Q3, 2024 Results on Oct 30, 2024

Biogen Inc. Announces Elects Lloyd B. Minor and Sir Menelas (Mene) Pangalos as Directors, Effective October 1, 2024 and January 1, 2025, Respectively

Second quarter 2024 earnings released: EPS: US$4.01 (vs US$4.09 in 2Q 2023)

Eisai Co., Ltd. and Biogen Inc. Update on Regulatory Review of Lecanemab for Early Alzheimer's Disease in the European Union

Sage Therapeutics and Biogen Announce Topline Results from Phase 2 KINETIC 2 Study of Sage-324 (BIIB124) for the Treatment of Essential Tremor

Biogen Inc. (NasdaqGS:BIIB) completed the acquisition of Human Immunology Biosciences, Inc. from a group of sellers.

Eisai Co., Ltd. and Biogen Inc. Announces Launch of Leqembi in China

Biogen Inc. to Report Q2, 2024 Results on Aug 01, 2024

Biogen Inc. (NasdaqGS:BIIB) agreed to acquire Human Immunology Biosciences, Inc. from Alpha Wave Global, LP, Jeito Capital S.A., Viking Global Investors LP and others for approximately $1.8 billion.

Biogen and Ionis Announce Topline Phase 1/2 Study Results of Investigational Drug in Amyotrophic Lateral Sclerosis

Eisai Initiates Rolling Biologics License Application to US FDA for LEQEMBI® (Lecanemab-Irmb) for Subcutaneous Maintenance Dosing for the Treatment of Early Alzheimer's Disease Under the Fast Track Status

Biogen Inc., Annual General Meeting, Jun 20, 2024

Biogen Inc. Receives Positive CHMP Opinion for TOFIDence (tocilizumab), a Biosimilar Referencing ROACTEMRA

First quarter 2024 earnings released: EPS: US$2.71 (vs US$2.69 in 1Q 2023)

Biogen Inc. Provides Earnings Guidance for the Full Year of 2024

Biogen Inc. to Report Q1, 2024 Results on Apr 24, 2024

Executive VP recently sold US$20k worth of stock

Full year 2023 earnings released: EPS: US$8.02 (vs US$20.97 in FY 2022)

Biogen Inc. Announces Plans to Reprioritize its Resources in Alzheimer’s Disease, Strategic Therapeutic Area Expected to Drive Near and Long-Term Growth

Biogen Inc. to Report Q4, 2023 Results on Feb 13, 2024

CHMP Issues Positive Opinion for Biogen Inc.'s SKYCLARYS(R) (omaveloxolone), the First Therapy to Treat Friedreich's Ataxia

Sage Therapeutics, Inc. and Biogen Inc. Announces ZURZUVAE (Zuranolone) 50 mg (Two 25 mg Capsules Per Day) CIV

Biogen Inc. Updates Revenue Guidance for the Fiscal Year 2023

Third quarter 2023 earnings released: US$0.47 loss per share (vs US$7.86 profit in 3Q 2022)

Biogen Inc. Appoints Monish Patolawala to Its Board of Directors, Effective from January 1, 2024

Eisai Co., Ltd. and Biogen Inc. announces Eisai presented new data for LEQEMBI® (lecanemab-irmb) 100 mg/mL injection for intravenous (IV) use, in the Late Breaking Symposium 4 ‘Lecanemab for Early Alzheimer's Disease

Biogen Inc. to Report Q3, 2023 Results on Nov 08, 2023

FDA Approves Biogen Inc.'s TOFIDENCE™ (tocilizumab-bavi), a Biosimilar Referencing ACTEMRA®

Biogen Inc. (NasdaqGS:BIIB) acquired Reata Pharmaceuticals, Inc. (NasdaqGM:RETA).

Eisai Co., Ltd. and Biogen Inc. Announces LEQEMBI Intravenous Infusion (Lecanemab) Approved for the Treatment of Alzheimer’S Disease in Japan